At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ
Unlock the market timeline & signal feed
New Marketing & PR activity — 6 fresh signals just appeared.
The order this company entered each market — oldest to newest
Merck Launches Sotatercept in China
Eisai Presents Lenvatinib Data at ASCO 2026
Sign up to see the full signal feed
How Merck's international expansion compares to its competitors
MerckYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 MerckYou | 16 | 5 | -39% | 29 | 23 |
Senior Specialist, Image Data Analytics
View postingRahway, NJ · 3d ago
Senior Specialist, Image Data Analytics
View postingCambridge, MA · 3d ago
Senior Specialist, Image Data Analytics
View postingWest Point, PA · 3d ago
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Kelun-Biotech will present clinical data on three oncology products at ASCO 2026, including TROP2 ADC sacituzumab tirumotecan, RET inhibitor lunbotinib fumarate, and novel ADC SKB500 for various cancer treatments.
Google unveiled 8th generation TPU chips at Cloud Next 2026, featuring TPU 8T for training (3x faster) and TPU 8I for inference (8x performance boost), intensifying cloud AI competition with Microsoft and Amazon.
D3 Bio's elisrasib achieved 78% ORR as monotherapy and 81.3% ORR combined with pembrolizumab in first-line KRAS G12C-mutant NSCLC, with favorable safety profiles across PD-L1 expression levels.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Merck's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
